Optimal ‘salvage’ chemotherapy in patients with relapsed ovarian following front line chemotherapy. The question as to the optimal therapy for patients, who relapse following first line therapies in ovarian cancer, is contreversial.
In patients who did well for some years after remitting on platinum and taxane chemotherapy, it is well worthwhile to trial their cancer again with the same combination of drugs. However, where the patient fails early after such chemotherapy or ultimately fails from such chemotherapy, then alternative active drug regimens are sought. Drugs such as adriamycin and topotecan are well discussed in a recent review article and the possible role of new agents such as herceptin (see breast cancer section) is discussed.